Skip to main content
. Author manuscript; available in PMC: 2019 Nov 2.
Published in final edited form as: Lancet HIV. 2019 Sep 27;6(11):e800–e806. doi: 10.1016/S2352-3018(19)30227-9

Figure 2. Population+ of 125 Who Would Seroconvert without PrEP. (a) TDF/FTC* Alone (b) PrEP LA** Alone (c) TDF/FTC and PrEP LA Offered as Choice: Redundant Scenario.

Figure 2

Note:

Panel 2 (a) Blue: Infections averted by TDF/FTC

Panel 2 (b) Red: Infections averted by PrEP LA

Latent Strata in Panel 2 (c)

Purple: Flexible (infections prevented by use of either TDF/FTC or PrEP LA), n=33

Blue: Pill-Preferred (infections averted by TDF/FTC but not by the PrEP LA), n=11

Red: PrEP LA Adopters (infected if offered TDF/FTC but averted by the PrEP LA), n=0

Black: Unreached (infected if provided TDF/FTC or PrEP LA), n=81

+ In this Figure, the same 125 individuals are displayed under three scenarios. Figures in the same position across the graphs identify the same individual.

*TDF/FTC: co-formulated tenofovir disoproxil fumarate and emtricitabine

**PrEP LA: non-daily and/or non-oral pre-exposure prophylaxis agent